The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Comparison of Survival and Quality of Life in Advanced Non–Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial
Abstract
PURPOSE: Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non–small-cell lung cancer (NSCLC). To determine whether a new agent, paclitaxel, would further improve survival in NSCLC, the Eastern Cooperative Oncology Group conducted a randomized trial comparing paclitaxel plus cisplatin to a standard chemotherapy regimen consisting of cisplatin and etoposide. PATIENTS AND METHODS: The study was carried out by a multi-institutional cooperative group in chemotherapy-naive stage IIIB to IV NSCLC patients randomized to receive paclitaxel plus cisplatin or etoposide plus cisplatin. Paclitaxel was administered at two different dose levels (135 mg/m 2 and 250 mg/m 2), and etoposide was given at a dose of 100 mg/m 2 daily on days 1 to 3. Each regimen was repeated every 21 days and each included cisplatin (75 mg/m 2). RESULTS: The characteristics of the 599 patients were well-balanced across the three treatment groups. Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P = .048). Comparing survival for the two dose levels of paclitaxel revealed no significant difference. The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P = .152). For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P = .246). With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms. Quality of life (QOL) declined significantly over the 6 months. However, QOL scores were not significantly different among the regimens. CONCLUSION: As a result of these observations, paclitaxel (135 mg/m 2) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Use of Ranks in One-Criterion Variance Analysis
Kruskal, W. H., & Wallis, W. A. (1952) · Journal of the American Statistical Association · doi:10.1080/01621459.1952.10483441 · Cited by 13,912
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Statistical Methods for Research Workers
(1945) · American Journal of Clinical Pathology · doi:10.1093/ajcp/15.11.552b · Cited by 10,880
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Landis, S. H., Murray, T., Bolden, S., & Wingo, P. A. (1999) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.49.1.8 · Cited by 3,068
Non-small Cell Lung Cancer Collaborative Group (1995) · BMJ · doi:10.1136/bmj.311.7010.899 · Cited by 2,850
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Brady, M. J., Cella, D. F., Mo, F., Bonomi, A. E., Tulsky, D. S., Lloyd, S. R., Deasy, S., Cobleigh, M., & Shiomoto, G. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.974 · Cited by 1,752
Self-citationKelly, K., Crowley, J., Bunn, P. A., Presant, C. A., Grevstad, P. K., Moinpour, C. M., Ramsey, S. D., Wozniak, A. J., Weiss, G. R., Moore, D. F., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3210 · Cited by 1,123
Cella, D. F., Bonomi, A. E., Lloyd, S. R., Tulsky, D. S., Kaplan, E., & Bonomi, P. (1995) · Lung Cancer · doi:10.1016/0169-5002(95)00450-f · Cited by 750
Self-citationWozniak, A. J., Crowley, J. J., Balcerzak, S. P., Weiss, G. R., Spiridonidis, C. H., Baker, L. H., Albain, K. S., Kelly, K., Taylor, S. A., Gandara, D. R., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2459 · Cited by 555
Phase II Study of Taxol in Patients With Untreated Advanced Non-Small-Cell Lung Cancer
Murphy, W. K., Fossella, F. V., Winn, R. J., Shin, D. M., Hynes, H. E., Gross, H. M., Davilla, E., Leimert, J., Dhingra, H., Raber, M. N., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.384 · Cited by 429
Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?
Grilli, R., Oxman, A. D., & Julian, J. A. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.10.1866 · Cited by 382
A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer.
Ruckdeschel, J. C., Finkelstein, D. M., Ettinger, D. S., Creech, R. H., Mason, B. A., Joss, R., & Vogl, S. E. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.1.14 · Cited by 338
Chang, A. Y., Kim, K., Glick, J., Anderson, T., Karp, D., & Johnson, D. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.388 · Cited by 336
Self-citationFinkelstein, D. M., Ettinger, D. S., & Ruckdeschel, J. C. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.5.702 · Cited by 325
Bonomi, P. D., Finkelstein, D. M., Ruckdeschel, J. C., Blum, R. H., Green, M. D., Mason, B., Hahn, R., Tormey, D. C., Harris, J., & Comis, R. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.11.1602 · Cited by 323
Self-citationGiaccone, G., Splinter, T. A., Debruyne, C., Kho, G. S., Lianes, P., van Zandwijk, N., Pennucci, M. C., Scagliotti, G., van Meerbeeck, J., van Hoesel, Q., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2133 · Cited by 275
Gatzemeier, U., von Pawel, J., Gottfried, M., Velde, G. P. M. T., Mattson, K., DeMarinis, F., Harper, P., Salvati, F., Robinet, G., Lucenti, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.19.3390 · Cited by 226
Rowinsky, E. K., Chaudhry, V, Forastiere, A. A., Sartorius, S. E., Ettinger, D. S., Grochow, L. B., Lubejko, B. G., Cornblath, D. R., & Donehower, R. C. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.10.2010 · Cited by 192
Self-citationFairclough, D. L., Peterson, H. F., Cella, D. F., & Bonomi, P. (1998) · Statistics in Medicine · Cited by 122
Self-citation
Cited by
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
Temel, J. S., Greer, J. A., Muzikansky, A., Gallagher, E. R., Admane, S., Jackson, V. A., Dahlin, C. M., Blinderman, C. D., Jacobsen, J., Pirl, W. F., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000678 · Cited by 7,482
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Self-citationVinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
Winton, T., Livingston, R., Johnson, D., Rigas, J., Johnston, M., Butts, C., Cormier, Y., Goss, G., Inculet, R., Vallieres, E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043623 · Cited by 1,810
Self-citationPfister, D. G., Johnson, D. H., Azzoli, C. G., Sause, W., Smith, T. J., Baker Jr, S., Olak, J., Stover, D., Strawn, J. R., Turrisi, A. T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.053 · Cited by 1,413
Self-citationKelly, K., Crowley, J., Bunn, P. A., Presant, C. A., Grevstad, P. K., Moinpour, C. M., Ramsey, S. D., Wozniak, A. J., Weiss, G. R., Moore, D. F., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3210 · Cited by 1,123
Metadata
- Authors
- Bonomi, P., Kim, K., Fairclough, D., Cella, D., Kugler, J., Rowinsky, E., Jiroutek, M., & Johnson, D.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-02-01
- Volume
- 18
- Issue
- 3
- Pages
- 623-623
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1868450210
- Cited by
- 589
- References
- 24
- FWCI
- 53.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.